Johnson & Johnson Highlights P-III Clinical Data of Icotrokinra for Plaque Psoriasis at AAD 2025
Shots:
- J&J has reported P-III trial data incl. ICONIC-LEAD (vs PBO) & ICONIC-ADVANCE 1&2 (vs Sotyktu) assessing icotrokinra (JNJ-2113, QD, PO) to treat mod. to sev. plaque PsO
- ICONIC-LEAD showed that pts achieved IGA 0/1 (65% vs 8%) & reached PASI 90 (50% vs 4%) at 16wks. By Wk. 24, 74% achieved IGA 0/1, 65% reached PASI 90, & ~50% had completely clear skin (46% IGA 0 & 40% PASI100); data from subgroup (adolescent) analysis to be presented at future meeting
- Additionally, ICONIC-ADVANCE-1 & 2 met its co-1EPs (IGA 0/1 & PASI 90) at 16wks. & all 2EPs at Wks. 16-24, showing superiority to Sotyktu. Also, J&J will advance P-III (ICONIC-ASCEND) trial, comparing icotrokinra to Stelara & PBO
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- The US FDA Approves sNDA for J&J’s Spravato (esketamine) to Treat Major Depressive Disorder (MDD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
